PGIM Jennison Health Sciences Fund (PHSZX)
$
)
Awards
Barron’s Best Fund Families: Ranked #4 for best fund family over the 1-year period ended 12/31/2024, among 48 qualifying fund families based on asset- weighted returns.
Seeks long-term capital appreciation by investing in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, and healthcare service providers. The Fund may be appropriate for those seeking the growth potential associated with the healthcare sector and can withstand the volatility associated with sector investing.
Growth of $10,000
Past performance does not guarantee future results and current performance may be lower or higher than the past performance data quoted. The investment return and principal value will fluctuate, and shares, when sold, may be worth more or less than the original cost. This chart represents historical performance and does not assume the effects of sales charges or varying fees and expenses of other share classes. If shown with sales charges or these other fees and expenses, performance could have been lower. It is not possible to invest directly in an index. Click here to view benchmark index definitions.
FUND INFORMATION
Fund Statistics
|
Name
|
Weight
|
|---|---|
| Avg Weighted Market Cap ($mil) | 179,886.60 |
| Beta (3 year) | 0.90 |
| Standard Deviation (3 year) | 14.01 |
| Turnover Ratio (12-month %) | 79.00 |
Source: Morningstar. Morningstar Ratings may be calculated based on share class adjusted historical returns. If so, the fund’s independent Morningstar Rating metric uses the fund’s oldest class to determine its hypothetical rating for certain periods. Morningstar Ratings are calculated for managed products with a 3-year minimum history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. Rating is calculated based on a Morningstar Risk-Adjusted Return measure accounting for variation in a managed product's monthly excess performance that emphasizes downward variations more and rewards consistent performance, with no sales load adjustment. In each category, the top 10% receive 5 stars, with 4 stars for the next 22.5%, 3 stars for the next 35%, 2 stars for the next 22.5%, and 1 star for the bottom 10%. Overall Morningstar Rating is derived from a weighted average of the performance associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics: for 36-59 months of total returns, 100% 3-year rating, for 60-119 months of total returns, 60% 5-year rating/40% 3-year rating, and for 120 or more months of total returns, 50% 10-year rating/30% 5-year rating/20% 3-year rating.
The LSEG Lipper Fund Awards, granted annually, highlight funds and fund companies that have excelled in delivering consistently strong risk-adjusted performance relative to their peers. The LSEG Lipper Fund Awards are based on the Lipper Leader for Consistent Return rating, which is an objective, quantitative, risk-adjusted performance measure calculated over 36, 60 and 120 months. The fund with the highest Lipper Leader for Consistent Return (Effective Return) value in each eligible classification wins the LSEG Lipper Fund Award. For more information, see lipperfundawards.com. Although LSEG Lipper makes reasonable efforts to ensure the accuracy and reliability of the data used to calculate the awards, their accuracy is not guaranteed. LSEG Lipper Fund Awards, © 2025 LSEG. All rights reserved. Used under license.
PGIM Jennison Health Sciences Fund (Class R6) total return ranking for the 1-year period: 33/133 funds as of 11/30/2024. Inception date: Class R6: 01/27/2016. Lipper Funds category rankings are based on total return, do not take sales charges into account, and are calculated against all funds in each fund’s respective Lipper category.
Class R6 Lipper total return ranking for the 1-, 3-, and 5-year periods as of 6/30/2025 for the Health/Biotechnology Fund category were: 81/129, 13/125, and 5/116 funds, respectively. Past performance is no guarantee of future results.
The Morningstar Medalist RatingTM is the summary expression of Morningstar’s forward-looking investment strategies analysis offered via specific vehicles on a Gold, Silver, Bronze, Neutral, and Negative scale. These ratings indicate the investments Morningstar believes are likely to outperform a relevant index or peer group average on a risk-adjusted basis over time. Investments are evaluated on 3 pillars (People, Parent, and Process) which, when coupled with a fee assessment, form the basis for Morningstar’s conviction in those product’s investment merits and determine the assigned rating. Pillar ratings are Low, Below Average, Average, Above Average, and High, and are evaluated qualitatively (either directly to a covered vehicle or indirectly when a covered vehicle’s ratings are mapped to a related uncovered vehicle) or using algorithmic techniques. Vehicles are sorted by expected performance into rating groups defined by their Morningstar Category and active or passive status. Analysts who directly cover a vehicle assign the 3 pillar ratings based on their qualitative assessment, subject to Analyst Rating Committee oversight, and monitor and reevaluate them at least every 14 months. Vehicle ratings are assigned monthly when covered either indirectly by analysts or by algorithm. For more information, please visit www.global.morningstar.com/managerdisclosures/. Ratings are not statements of fact, nor are they credit or risk ratings. The Morningstar Medalist Rating (i) should not be used as the sole basis in evaluating an investment product, (ii) involves unknown risks and uncertainties which may cause expectations not to occur or to differ significantly from what was expected, (iii) are not guaranteed to be based on complete or accurate assumptions or models when determined algorithmically, (iv) involve the risk that the return target will not be met due to issues like unforeseen changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rates, exchange rate changes, and/or changes in political and social conditions, and (v) should not be considered an offer or solicitation to buy or sell the investment. Changes in underlying factors can mean the rating is subsequently no longer accurate. ‡Source: Morningstar.
Risks of investing in the fund include but are not limited to the following: The Fund concentrates in investments in health sciences companies, which may be relatively small and thinly traded, have persistent losses during a new product’s transition from development to production, or erratic revenue patterns, and may be under regulatory scrutiny and are subject to risks of the adverse impact of legislative actions and government regulations. Growth style investing may subject the Fund to above-average fluctuations as a result of seeking higher than average capital growth. Equity and equity-related securities may be subject to changes in value, and their values may be more volatile than those of other asset classes. Small- and Mid-cap investments may be subject to more erratic market movements than large-cap stocks. Foreign securities are subject to currency fluctuations and political uncertainty. Investments in currency may result in a decline in the fund’s net asset value due to changes in exchange rates. There is no guarantee the Fund's objective will be achieved. Risks are more fully explained in the fund's prospectus.
- Monthly & Quarterly Performance
- Prices & Yields
Total Returns (%)
| TOTAL RETURNS (%) WITH SALES CHARGE WITHOUT SALES CHARGE | |||||||
|---|---|---|---|---|---|---|---|
| Cumulative | Average Annual | ||||||
| Class | Ticker | YTD | 1-Yr | 3-Yr | 5-Yr | 10-Yr | Since Inception |
Past performance does not guarantee future results and current performance may be lower or higher than the past performance data quoted. The investment return and principal value will fluctuate, and shares, when sold, may be worth more or less than the original cost.
See Daily Returns for the PGIM Jennison Health Sciences Fund.
See Performance of other PGIM Investments Mutual Funds.
See Calendar Year Performance for the PGIM Jennison Health Sciences Fund.
See Daily Returns for the PGIM Jennison Health Sciences Fund.
See Quarterly SEC Standardized Performance of other PGIM Investments Mutual Funds.
See Calendar Year Performance for the PGIM Jennison Health Sciences Fund.
|
Fund Expenses
|
Maximum Sales Charge (%)
|
|||
|---|---|---|---|---|
|
Class
|
Gross (%)
|
Net (%)
|
Date*
|
|
| A | 1.13 | 1.13 | — | 5.50 |
| C | 1.96 | 1.96 | — | 1.00 |
| R | 1.73 | 1.48 | 03/31/2026 | — |
| R6 | 0.77 | 0.77 | — | — |
| Z | 0.86 | 0.86 | — | — |
*This date represents the contractual reduction date through which the net expense ratio is in effect.
Total return describes the return to the investor after net operating expenses but before any sales charges are imposed. Morningstar Category Average is unmanaged, is based on the average return of all funds in this category, and does not take into consideration applicable sales charges. Unless noted otherwise, Morningstar Category Average and index returns reflect performance beginning the closest month-end date to the Fund's inception. Benchmark since inception average is based on Class Z inception date. SEC standardized return describes the return to the investor after net operating expense and maximum sales charges are imposed. All returns assume share price changes as well as the compounding effect of reinvested dividends and capital gains. Returns may reflect fee waivers and/or expense reimbursements. Without such, returns would be lower. All returns 1-year or less are cumulative.
Morningstar Health Category Average: Health portfolios focus on the medical and health-care industries. Most invest in a range of companies, buying everything from pharmaceutical and medical-device makers to HMOs, hospitals, and nursing homes. A few portfolios concentrate on just one industry segment, such as service providers or biotechnology firms.
S&P 1500 Healthcare Index is capitalization-weighted index that measures the performance of the health care sector of the S&P Composite 1500 Index.
The S&P 1500 Healthcare Index is a product of S&P Dow Jones Indices LLC and/or its affiliates and has been licensed for use by PGIM Investments. Copyright ©2025 S&P Dow Jones Indices LLC, a division of S&P Global, Inc., and/or its affiliates. All rights reserved. Redistribution or reproduction in whole or in part are prohibited without written permission of S&P Dow Jones Indices LLC. For more information on any of S&P Dow Jones Indices LLC's indices please visit www.spdji.com. S&P® is a registered trademark of S&P Global and Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC.
An investment cannot be made directly in an index or average. All indexes and averages are unmanaged.
Prices
|
Class
|
NAV ($)
|
NAV Change ($)
|
NAV Change (%)
|
POP ($)
|
Total Net Assets ($)
|
|---|---|---|---|---|---|
| A | 31.01 |
-0.72
|
-2.27 | 32.81 | 525,894,059.50 |
| C | 11.37 |
-0.26
|
-2.24 | — | 10,266,455.39 |
| R | 28.54 |
-0.66
|
-2.26 | — | 4,730,999.39 |
| R6 | 40.23 |
-0.93
|
-2.26 | — | 32,590,007.28 |
| Z | 39.81 |
-0.92
|
-2.26 | — | 686,472,384.72 |
NAV (Net Asset Value) is the $U.S. value of a single share of a fund, excluding any sales charges. Change shows the change in $U.S. value over the previous day:
= Gain, 
= Loss, 
= No Change.
See Prices of other PGIM Investments Mutual Funds.
52 Week High/Low
|
Class
|
52 Week High ($)
|
52 Week High Date
|
52 Week Low ($)
|
52 Week Low Date
|
|---|---|---|---|---|
| A | 43.93 | 08/30/2024 | 29.55 | 04/08/2025 |
| C | 19.91 | 08/30/2024 | 10.87 | 04/08/2025 |
| R | 40.92 | 08/30/2024 | 27.23 | 04/08/2025 |
| R6 | 55.21 | 08/30/2024 | 38.29 | 04/08/2025 |
| Z | 54.68 | 08/30/2024 | 37.90 | 04/08/2025 |
For share classes less than one year old, the 52-week high and 52-week low NAVs are calculated from inception to the current date.
See Yields of other PGIM Investments Mutual Funds.
Past performance does not guarantee future results and current performance may be lower or higher than the past performance data quoted. The investment return and principal value will fluctuate, and shares, when sold, may be worth more or less than the original cost.
This material must be preceded or accompanied by a current prospectus or summary prospectus. Consider a fund's investment objectives, risks, charges, and expenses carefully before investing. The prospectus and summary prospectus contain this and other information about the fund. For more information about a fund, click on the prospectus or summary prospectus link above. Read them carefully before investing.
- Portfolio Summary
- Complete Holdings
Portfolio Attributes
All data is unaudited and subject to change. Holdings/allocations may vary. This is not a recommendation to buy or sell any security listed. Largest holdings excludes cash, cash equivalents, money market funds and enhanced cash strategies. Totals may not sum due to rounding.
*Diversified sector represents real estate companies that own properties across multiple sectors.
Fund Holdings
Holdings are unaudited, may vary and are subject to change. Please refer to the Fund's annual report for audited holdings information. This is not a recommendation to buy or sell any security listed.
Value ($): Cash securities are calculated using market value and derivative securities are calculated using notional value.
Source: Bank of New York Mellon. Holdings are provided to Prudential Financial by the custodian bank and Prudential Financial is not responsible for any errors or omissions related to the holdings data.
© 2025, American Bankers Association. CUSIP Database provided by FactSet Research Systems Inc. All rights reserved.
Consider a fund's investment objectives, risks, charges and expenses carefully before investing. The prospectus and summary prospectus contain this and other information about the fund. For more information about a fund, click on the prospectus or summary prospectus link above. Read them carefully before investing.
Investment products are distributed by Prudential Investment Management Services LLC, member FINRA and SIPC. PGIM Investments is a registered investment advisor and investment manager to PGIM registered investment companies. Jennison Associates is a registered investment advisor. PGIM Quantitative Solutions is the primary business name of PGIM Quantitative Solutions LLC, a registered investment advisor. PGIM Fixed Income and PGIM Real Estate are units of PGIM, a registered investment advisor. PGIM DC Solutions is a registered investment advisor. PGIM Limited acts as a subadvisor to all fixed income funds. PGIM Limited is an indirect, wholly owned subsidiary of PGIM, Inc. (PGIM), the principal asset management business of Prudential Financial, Inc. (PFI), a company incorporated and with its principal place of business in the United States. All are Prudential Financial affiliates. © 2025 Prudential Financial, Inc. and its related entities. PGIM, PGIM Investments, Jennison Associates, Jennison, PGIM Fixed Income, PGIM Limited, PGIM Quantitative Solutions, PGIM Real Estate, PGIM DC Solutions and the PGIM logo are service marks of Prudential Financial, Inc. and its related entities, registered in many jurisdictions worldwide.
This material is being provided for informational or educational purposes only and does not take into account the investment objectives or financial situation of any client or prospective clients. The information is not intended as investment advice and is not a recommendation. Clients seeking information regarding their particular investment needs should contact their financial professional.
INVESTMENT PRODUCTS | Are not insured by the FDIC or any federal government agency | May lose value | Are not a deposit of or guaranteed by any bank or any bank affiliate.
Prudential Financial, Inc. of the United States is not affiliated in any manner with Prudential plc, incorporated in the United Kingdom or with Prudential Assurance Company, a subsidiary of M&G plc, incorporated in the United Kingdom.
4072323 Ed. 12/2024
|
Security ID# (CUSIP/SEDOL)
|
Security Description
|
Ticker Symbol
|
Coupon Rate
|
Maturity Date
|
Shares/Notional
|
Value ($)
|
% of Portfolio
|
|---|---|---|---|---|---|---|---|
| 532457108 | ELI Lilly & Co | LLY | — | — | 265,302.00 | 206,810,868.00 | 15.19 |
| 002824100 | Abbott Laboratories | ABT | — | — | 513,503.00 | 69,841,543.00 | 5.13 |
| 92532F100 | Vertex Pharmaceuticals Inc | VRTX | — | — | 150,218.00 | 66,877,053.00 | 4.91 |
| 46120E602 | Intuitive Surgical Inc | ISRG | — | — | 117,504.00 | 63,852,848.00 | 4.69 |
| 04016X101 | Argenx Se | ARGX | — | — | 113,310.00 | 62,458,738.00 | 4.59 |
| 375558103 | Gilead Sciences Inc | GILD | — | — | 437,030.00 | 48,453,516.00 | 3.56 |
| 883556102 | Thermo Fisher Scientific Inc | TMO | — | — | 118,988.00 | 48,244,874.00 | 3.54 |
| 64125C109 | Neurocrine Biosciences Inc | NBIX | — | — | 381,142.00 | 47,905,737.00 | 3.52 |
| 670100205 | NOVO Nordisk A/s | NVO | — | — | 655,469.00 | 45,240,470.00 | 3.32 |
| 02043Q107 | Alnylam Pharmaceuticals Inc | ALNY | — | — | 134,897.00 | 43,988,562.00 | 3.23 |
| 91324P102 | Unitedhealth Group Inc | UNH | — | — | 126,565.00 | 39,484,483.00 | 2.90 |
| 5596991 | UCB Sa | UCB | — | — | 197,591.00 | 38,877,576.00 | 2.86 |
| 7333378 | Lonza Group Ag | LONN | — | — | 49,206.00 | 35,190,333.00 | 2.59 |
| 74440W862 | (pipa070) Pgim Core Government Money Mar | — | 4.42 | 12/01/2099 | 33,804,735.00 | 33,804,734.00 | 2.48 |
| 046353108 | Astrazeneca Plc | AZN | — | — | 469,600.00 | 32,815,648.00 | 2.41 |
| 03969K108 | Arcutis Biotherapeutics Inc | ARQT | — | — | 2,269,514.00 | 31,818,586.00 | 2.34 |
| 126650100 | CVS Health Corp | CVS | — | — | 428,269.00 | 29,541,995.00 | 2.17 |
| 235851102 | Danaher Corp | DHR | — | — | 140,737.00 | 27,801,186.00 | 2.04 |
| 36266G107 | GE Healthcare Technologies Inc | GEHC | — | — | 358,242.00 | 26,534,984.00 | 1.95 |
| 457669307 | Insmed Inc | INSM | — | — | 234,427.00 | 23,592,733.00 | 1.73 |
| 501575104 | Kymera Therapeutics Inc | KYMR | — | — | 523,510.00 | 22,845,976.00 | 1.68 |
| 252131107 | Dexcom Inc | DXCM | — | — | 249,266.00 | 21,758,429.00 | 1.60 |
| 714046109 | Revvity Inc | RVTY | — | — | 219,203.00 | 21,201,314.00 | 1.56 |
| 28176E108 | Edwards Lifesciences Corp | EW | — | — | 263,382.00 | 20,599,106.00 | 1.51 |
| 925050106 | Verona Pharma Plc | VRNA | — | — | 217,507.00 | 20,571,812.00 | 1.51 |
| 22663K107 | Crinetics Pharmaceuticals Inc | CRNX | — | — | 675,458.00 | 19,426,172.00 | 1.43 |
| 03753U106 | Apellis Pharmaceuticals Inc | APLS | — | — | 1,124,507.00 | 19,465,216.00 | 1.43 |
| 92243G108 | Vaxcyte Inc | PCVX | — | — | 585,342.00 | 19,029,468.00 | 1.40 |
| 87650L103 | Tarsus Pharmaceuticals Inc | TARS | — | — | 382,765.00 | 15,505,810.00 | 1.14 |
| BQ7ZV06 | Straumann Holding Ag | STMN | — | — | 114,927.00 | 15,042,762.00 | 1.11 |
| 00846U101 | Agilent Technologies Inc | A | — | — | 119,556.00 | 14,108,803.00 | 1.04 |
| BP8JSP4 | Newamsterdam Pharma Co Nv | NAMS | — | — | 777,280.00 | 14,076,540.00 | 1.03 |
| 875372203 | Tandem Diabetes Care Inc | TNDM | — | — | 732,318.00 | 13,650,407.00 | 1.00 |
| 98420N105 | Xenon Pharmaceuticals Inc | XENE | — | — | 407,083.00 | 12,741,697.00 | 0.94 |
| BNM0752 | Stevanato Group Spa | STVN | — | — | 523,209.00 | 12,781,995.00 | 0.94 |
| 603170101 | Mineralys Therapeutics Inc | MLYS | — | — | 738,891.00 | 9,997,195.00 | 0.73 |
| 829401108 | Sionna Therapeutics Inc | SION | — | — | 553,942.00 | 9,610,893.00 | 0.71 |
| 40131M109 | Guardant Health Inc | GH | — | — | 144,677.00 | 7,528,991.00 | 0.55 |
| 632307104 | Natera Inc | NTRA | — | — | 41,292.00 | 6,975,870.00 | 0.51 |
| 59267L107 | Metsera Inc | MTSR | — | — | 221,101.00 | 6,290,323.00 | 0.46 |
| 89422G107 | Travere Therapeutics Inc | TVTX | — | — | 393,263.00 | 5,820,292.00 | 0.43 |
| 80706P103 | Scholar Rock Holding Corp | SRRK | — | — | 158,182.00 | 5,602,806.00 | 0.41 |
| 81663L200 | Genedx Holdings Corp | WGS | — | — | 60,734.00 | 5,606,355.00 | 0.41 |
| 12674W109 | Cabaletta Bio Inc | CABA | — | — | 3,518,102.00 | 5,347,515.00 | 0.39 |
| 03770N101 | Apogee Therapeutics Inc | APGE | — | — | 112,496.00 | 4,885,701.00 | 0.36 |
| CURRENCY | Currency | — | — | — | 3,429,222.00 | 3,429,222.00 | 0.25 |
| 142152107 | Caris Life Sciences Inc | CAI | — | — | 50,295.00 | 1,343,882.00 | 0.10 |
| BSJQPL0 | Kestra Medical Technologies Ltd | KMTS | — | — | 77,529.00 | 1,285,430.00 | 0.09 |
| 68170A108 | Omada Health Inc | OMDA | — | — | 43,384.00 | 793,927.00 | 0.06 |
| 08659B102 | BETA Bionics Inc | BBNX | — | — | 43,415.00 | 632,122.00 | 0.05 |
| CABAW9999 | Cabaletta Bio Inc Warrant | — | — | 09/11/2026 | 2,139,298.00 | 21.00 | 0.00 |
The CUSIP information contained in pgimfunds.com and/or prudential.com consists of security identifiers and related descriptive information (“the CUSIP Database”) and is protected under the copyright laws and is licensed with permission from CUSIP Global Services (“CGS”), on behalf of the American Bankers Association (“ABA”).
VISITOR agrees and acknowledges that the CUSIP Database and the information contained therein is and shall remain valuable intellectual property owned by, or licensed to, CGS and ABA, and that no proprietary rights are being transferred to VISITOR in such materials or in any of the information contained therein by virtue of VISITOR’s use of Subscriber’s Web Site. Any use of the CUSIP Database by VISITOR outside of the clearing and settlement of transactions may require a license from CGS, along with an associated fee based on usage.
VISITOR agrees that misappropriation or misuse of such materials will cause serious damage to CGS and ABA, and that in such event, money damages may not constitute sufficient compensation to CGS and ABA; consequently, VISITOR agrees that in the event of any misappropriation or misuse, CGS and ABA shall have the right to obtain injunctive relief in addition to any other legal or financial remedies to which CGS and ABA may be entitled.
VISITOR agrees that VISITOR shall not publish or distribute in any medium the CUSIP Database or any substantial portion of the information contained therein or summaries or subsets thereof to any person or entity unless permitted by a direct agreement with CGS. VISITOR may not create or maintain a master file or database of CUSIP identifiers or descriptions for itself or any third party recipient that is intended to serve as a substitute for any CUSIP service.
VISITOR agrees not to:
(a) Violate the restrictions in any robot inclusion headers on the Subscriber Web Site or in any way bypass or circumvent any other measure employed to limit or prevent access to the CUSIP Database on the Subscriber Web Site;
(b) Violate the security of the Subscriber Web Site or attempt to gain unauthorized access to the Web Site, CUSIP Database, materials, information, computer systems or networks connected to Subscriber server, through hacking, password mining or any other means; or
(c) Interfere or attempt to interfere with the proper working of the Subscriber Web Site or any activities conducted on or through the Subscriber Web Site, including accessing any CUSIP Database, content or other information prior to the time that is intended to be available to the public on the Subscriber Web Site;
NEITHER CGS, ABA NOR ANY OF THEIR AFFILIATES MAKE ANY WARRANTIES, EXPRESS OR IMPLIED, AS TO THE ACCURACY, ADEQUACY OR COMPLETENESS OF ANY OF THE INFORMATION CONTAINED IN THE CUSIP DATABASE. ALL SUCH MATERIALS ARE PROVIDED TO VISITOR ON AN “AS IS” BASIS, WITHOUT ANY WARRANTIES AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE NOR WITH RESPECT TO THE RESULTS WHICH MAY BE OBTAINED FROM THE USE OF SUCH MATERIALS. NEITHER CGS, ABA NOR THEIR AFFILIATES SHALL HAVE ANY RESPONSIBILITY OR LIABILITY FOR ANY ERRORS OR OMISSIONS NOR SHALL THEY BE LIABLE FOR ANY DAMAGES, WHETHER DIRECT OR INDIRECT, SPECIAL OR CONSEQUENTIAL, EVEN IF THEY HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT SHALL THE LIABILITY OF CGS, ABA OR ANY OF THEIR AFFILIATES PURSUANT TO ANY CAUSE OF ACTION, WHETHER IN CONTRACT, TORT, OR OTHERWISE, EXCEED THE FEE PAID BY VISITOR FOR ACCESS TO SUCH MATERIALS IN THE MONTH IN WHICH SUCH CAUSE OF ACTION IS ALLEGED TO HAVE ARISEN. FURTHERMORE, CGS AND ABA SHALL HAVE NO RESPONSIBILITY OR LIABILITY FOR DELAYS OR FAILURES DUE TO CIRCUMSTANCES BEYOND THEIR CONTROL.
VISITOR agrees that the foregoing terms and conditions shall survive any termination of its right of access to the materials identified above.
ABOUT
?ts=1754526443801&dpr=off)
Jennison Associates is one of the nation's leading managers of growth, value, blend, and specialty equity strategies. It has earned a reputation for excellence by fulfilling the needs of clients for more than 50 years.
Daniel Matviyenko, and Debra Netschert are the portfolio managers for the PGIM Jennison Health Sciences Fund.
Daniel Matviyenko
Managing Director and Portfolio Manager of Health Sciences
|Jennison Associates
Daniel Matviyenko is a Managing Director and Portfolio Manager of Health Sciences strategies at Jennison Associates.
Debra Netschert
Managing Director, Health Sciences Equity Portfolio Manager, and Research Analyst
|Jennison Associates
Debra Netschert is a Managing Director, health sciences equity portfolio manager, and research analyst.
Average weighted market capitalization is the average market capitalization of stocks in a fund, each weighted by its proportion of assets. Beta measures a fund's sensitivity to changes in the overall market relative to its benchmark. The P/E ratio (Source: Morningstar, Inc.) relates the price of a stock to the per-share earnings of the company. P/E is calculated using a harmonic weighted average, which excludes outliers that can easily skew results. Standard deviation depicts how widely returns vary around its average and is used to understand the range of returns most likely for a given fund. A higher standard deviation generally implies greater volatility. Turnover Ratio is the rate of trading in a portfolio, higher values imply more frequent trading. Beta is benchmarked against the S&P SuperComposite Health Care Index which is an unmanaged capitalization-weighted index that measures the performance of the health care sector of the S&P SC 1500 Index. An investment cannot be made directly in an index. Due to data availability, statistics may not be as of the current reporting period.
Enhanced cash strategies are variations on traditional money market vehicles. They are designed to provide liquidity and principal preservation, but with more of an emphasis on seeking returns that are superior to those of traditional money market offerings.
Source: Benchmarks - Lipper Inc.; Statistics - Morningstar Inc.; Sector classification - S&P/MSCI. *This figure is comprised of companies that have been classified by S&P/MSCI GICS or classified by Jennison Associates LLC. Companies classified by Jennison Associates LLC are not sponsored by the S&P/MSCI GICS classification system. All other data from PGIM, Inc. (PGIM).
© 2025 Morningstar, Inc. All rights reserved. The information contained herein (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance does not guarantee future results.
Class R shares are closed to new investors. Class R6 and Z shares may be available to group retirement plans and institutional investors through certain retirement, mutual fund wrap and asset allocation programs. They may also be available to institutional investors. Class Z shares may be available through fee- or commission-based retail brokerage programs of certain financial intermediaries. Class A, C, and Z shares are generally closed to new retirement plans. Please see the prospectus for additional information about fees, expenses, and investor eligibility.
Consider a fund's investment objectives, risks, charges and expenses carefully before investing. The prospectus and summary prospectus contain this and other information about the fund. For more information about a fund, click on the prospectus or summary prospectus link above. Read them carefully before investing.
Investment products are distributed by Prudential Investment Management Services LLC, member FINRA and SIPC. PGIM Investments is a registered investment advisor and investment manager to PGIM registered investment companies. Jennison Associates is a registered investment advisor. All are Prudential Financial affiliates. © 2025 Prudential Financial, Inc. and its related entities. PGIM, PGIM Investments, Jennison Associates, Jennison, and the PGIM logo are service marks of Prudential Financial, Inc. and its related entities, registered in many jurisdictions worldwide.
This material is being provided for informational or educational purposes only and does not take into account the investment objectives or financial situation of any client or prospective clients. The information is not intended as investment advice and is not a recommendation. Clients seeking information regarding their particular investment needs should contact their financial professional.
INVESTMENT PRODUCTS | Are not insured by the FDIC or any federal government agency | May lose value | Are not a deposit of or guaranteed by any bank or any bank affiliate.
Prudential Financial, Inc. of the United States is not affiliated in any manner with Prudential plc, incorporated in the United Kingdom or with Prudential Assurance Company, a subsidiary of M&G plc, incorporated in the United Kingdom.
4360298 Ed. 03/2025
Fund Literature
| document name | audience | updated | order code |
|---|
